Adeno-Associated Viral Vectors Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Adeno-Associated Viral Vectors Market Growth Performance Trended Historically, And What Lies Ahead?
The market size for adeno-associated viral vectors has seen a significant expansion in the past years. Its growth is predicted to rise from $2.69 billion in 2024 to $3.17 billion in 2025, registering a compound annual growth rate (CAGR) of 17.9%. This growth in the historical period can be credited to factors such as vaccine creation, an uptick in funding and investments, collaborations between academia and industry, extension of clinical trials, as well as heightened public awareness and advocacy.
What Is the Forecast for the Adeno-Associated Viral Vectors Market Size Through 2029?
The market size for adeno-associated viral vectors is anticipated to witness exponential growth in the upcoming years, reaching a value of $6.08 billion in 2029 with a compound annual growth rate (CAGR) of 17.6%. The projected growth during this forecast period is due to various factors including enhanced therapeutic applications, the rising incidence of genetic and neurological ailments, regulatory authorizations and backing, alongside production cost cuts. Key trends predicted to shape the forecast period encompass advancements in gene therapy, technological innovation, scalable production processes, collaboration and investment initiatives, and technological advancements.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp
What are the Key Market Players in Adeno-Associated Viral Vectors Market and How They’re Evolving?
Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics
What Are the Primary Growth Drivers in the Adeno-Associated Viral Vectors Market?
The escalating occurrence of genetic disorders is anticipated to boost the expansion of the adeno-associated viral vectors market. Genetic disorders, which are often characterized by DNA irregularities leading to physical or developmental anomalies, are becoming more commonplace. This rise is attributed to advanced diagnostic techniques, increased awareness, climatic factors, genetic drift, and higher reproductive age. Adeno-associated viral vectors, used in gene therapy for genetic disorders, deliver corrective genes into cells to potentially address conditions such as muscular dystrophy or cystic fibrosis. As per the World Health Organization (WHO), a Switzerland-based United Nations specialized agency for international public health, congenital diseases were responsible for roughly 240,000 neonatal deaths globally inside 28 days of birth annually, as reported in February 2023. Furthermore, congenital diseases contribute to the death of an additional 170,000 children aged between one month and five years. As such, the intensifying occurrence of genetic disorders is propelling the adeno-associated viral vectors market upwards.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=15969&type=smp
What Are the Leading Segments in the Global Adeno-Associated Viral Vectors Industry?
The adeno-associated viral vectors market covered in this report is segmented –
1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies
2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas
4) By Scale Of Operation: Preclinical, Clinical, Commercial
5) By Application Area: Gene Therapy, Cell Therapy, Vaccines
Subsegments:
1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia
2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy, Autoimmune Diseases Immunotherapy
3) By Other Types Of Therapies: Gene Editing, RNA Therapy, Antiviral Therapy
What Are the Key Market Trends in the Adeno-Associated Viral Vectors Industry?
Top businesses within the adeno-associated viral vectors marketplace are prioritizing the provision of readily available replication-capsid plasmid to create a competitive advantage. Rep/Cap plasmids, frequently used in adeno-associated virus (AAV) vector production for gene therapy, can be easily procured from a wide array of commercial vendors that cater to molecular biology research requirements. For instance, in January 2024, the US pharmaceutical firm, Charles River Laboratories International Inc., unveiled a range of off-the-shelf replication-capsid plasmid, which simplifies AAV-based gene therapy schemes. This addition to their product line pairs well with their existing lentiviral packaging and AAV Helper plasmid products, reducing manufacturing efforts by nearly 66%. These ready-for-use plasmids are produced in batches with careful documentation, complying with CMC regulations and accompanied by a Certificate of Analysis (COA), making it easier for IND and Clinical Trial Application (CTA) submissions.
Access The Full Report Here:
What Is the Regional Outlook for the Adeno-Associated Viral Vectors Market?
North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15969
This Report Delivers Insight On:
1. How big is the adeno-associated viral vectors market, and how is it changing globally?
2. Who are the major companies in the adeno-associated viral vectors market, and how are they performing?
3. What are the key opportunities and risks in the adeno-associated viral vectors market right now?
4. Which products or customer segments are growing the most in the adeno-associated viral vectors market?
5. What factors are helping or slowing down the growth of the adeno-associated viral vectors market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
